Flagship Pioneering spinout thinks it has a treatment for 'long Covid'

In a near-first for the biotech industry, Axcella Therapeutics Inc. is launching a clinical study investigating a new drug to treat "long Covid," a long-lasting version of the once-novel respiratory illness that is still little understood. Axcella (Nasdaq: AXLA) is teaming up with Oxford University on a Phase 2 trial testing out a drug that targets the mitochondria, which is linked to chronic fatigue when dysregulated or damaged. Severe fatigue is one of the hallmark symptoms of long Covid and one…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news